Despite numerous FDA approvals of biosimilars, they have not yet gained a significant stake in the U.S. marketplace, according to a recent analysis published in Forbes.
Prices, profits and promotional spend are closely linked. Reduce prices and promotion will plummet. But wait, the Republicans are in control. Accordingly, pharma, its marketing partners and even Wall Street often rest easy, especially when Republicans control Congress and the White House.
The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche Holding AG’s blockbuster cancer treatment Avastin.
Amgen Inc. and Allergan plc announced that the U.S. FDA approved Kanjinti (trastuzumab-anns) for all approved cancer indications of the reference product Herceptin.
New Subcutaneous Formulation of Celltrion Healthcare’s Biosimilar CT-P13 Shows Positive Results for Treatment of Rheumatoid Arthritis
Celltrion Healthcare presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with rheumatoid arthritis during the treatment period of one year.
This annual compilation reviews new developments, trends and outlooks in areas such as biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biosimulation.
The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.
Through consultation with physicians and patients, the Canadian Breast Cancer Network (CBCN) outlined five key recommendations for consideration when implementing biosimilars in oncology
EVERSANA and OptimizeRx Corp. announced their partnership to modernize the patient experience and improve health outcomes by combining a real-time electronic health records (EHR) network with customized, wraparound patient support services.
Novartis AG’s Sandoz division struck a deal with Taiwan’s EirGenix Inc. to market a biosimilar version of Roche’s Herceptin that is in late-stage development to treat some cancer tumors.
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.